Despite some pretty devastating news about their "golden drug" Avandia earlier this week, GSK is doing really well on other fronts. Their stock is holding steady at just under $40 a share (39.72) and they had a press release this morning that is really exciting for them.
They received word today that the European Commission has approved one of their drugs, Arixtra, for use in a new therapeutic indication. This drug is an anti coagulant that is now the only drug of its type approved for use in "the treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis ofthe lower limbs without concomitant deep-vein thrombosis." It is the only drug approved for this treatment in its class. This approval is great news for GSK.
No comments:
Post a Comment